Literature DB >> 26778735

Nilotinib as a risk factor for ischaemic stroke: A series of three cases.

J B Gómez-Galván1, S Borrego1, N Tovar2, L Llull3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26778735      PMCID： PMC5894889          DOI： 10.1016/j.nrl.2015.11.003

Source DB:  PubMed          Journal:  Neurologia        ISSN： 0213-4853            Impact factor:   3.109


× No keyword cloud information.
  13 in total

1.  2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

Authors:  David C Goff; Donald M Lloyd-Jones; Glen Bennett; Sean Coady; Ralph B D'Agostino; Raymond Gibbons; Philip Greenland; Daniel T Lackland; Daniel Levy; Christopher J O'Donnell; Jennifer G Robinson; J Sanford Schwartz; Susan T Shero; Sidney C Smith; Paul Sorlie; Neil J Stone; Peter W F Wilson; Harmon S Jordan; Lev Nevo; Janusz Wnek; Jeffrey L Anderson; Jonathan L Halperin; Nancy M Albert; Biykem Bozkurt; Ralph G Brindis; Lesley H Curtis; David DeMets; Judith S Hochman; Richard J Kovacs; E Magnus Ohman; Susan J Pressler; Frank W Sellke; Win-Kuang Shen; Sidney C Smith; Gordon F Tomaselli
Journal:  Circulation       Date:  2013-11-12       Impact factor: 29.690

2.  Fatal progressive cerebral ischemia in CML under third-line treatment with ponatinib.

Authors:  K Mayer; G H Gielen; W Willinek; M C Müller; D Wolf
Journal:  Leukemia       Date:  2013-10-30       Impact factor: 11.528

3.  Nilotinib-associated vascular events.

Authors:  Alfonso Quintás-Cardama; Hagop Kantarjian; Jorge Cortes
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2012-05-24

4.  European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts).

Authors:  Joep Perk; Guy De Backer; Helmut Gohlke; Ian Graham; Zeljko Reiner; Monique Verschuren; Christian Albus; Pascale Benlian; Gudrun Boysen; Renata Cifkova; Christi Deaton; Shah Ebrahim; Miles Fisher; Giuseppe Germano; Richard Hobbs; Arno Hoes; Sehnaz Karadeniz; Alessandro Mezzani; Eva Prescott; Lars Ryden; Martin Scherer; Mikko Syvänne; Wilma J M Scholte op Reimer; Christiaan Vrints; David Wood; Jose Luis Zamorano; Faiez Zannad
Journal:  Eur Heart J       Date:  2012-05-03       Impact factor: 29.983

5.  Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.

Authors:  Giuseppe Saglio; Dong-Wook Kim; Surapol Issaragrisil; Philipp le Coutre; Gabriel Etienne; Clarisse Lobo; Ricardo Pasquini; Richard E Clark; Andreas Hochhaus; Timothy P Hughes; Neil Gallagher; Albert Hoenekopp; Mei Dong; Ariful Haque; Richard A Larson; Hagop M Kantarjian
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

6.  Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML.

Authors:  Karl J Aichberger; Susanne Herndlhofer; Gerit-Holger Schernthaner; Martin Schillinger; Gerlinde Mitterbauer-Hohendanner; Christian Sillaber; Peter Valent
Journal:  Am J Hematol       Date:  2011-04-27       Impact factor: 10.047

7.  Nilotinib treatment-associated cerebrovascular disease and stroke.

Authors:  Elizabeth A Coon; Nicholas L Zalewski; Ernest Matthew Hoffman; Ayalew Tefferi; Kelly D Flemming
Journal:  Am J Hematol       Date:  2013-05-13       Impact factor: 10.047

8.  Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib.

Authors:  T D Kim; D Rea; M Schwarz; P Grille; F E Nicolini; G Rosti; L Levato; F J Giles; H Dombret; T Mirault; H Labussière; R Lindhorst; W Haverkamp; I Buschmann; B Dörken; P D le Coutre
Journal:  Leukemia       Date:  2013-03-05       Impact factor: 11.528

Review 9.  How I treat newly diagnosed chronic myeloid leukemia in 2015.

Authors:  Carlo Gambacorti-Passerini; Rocco Piazza
Journal:  Am J Hematol       Date:  2014-11-24       Impact factor: 10.047

10.  Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis.

Authors:  F J Giles; M J Mauro; F Hong; C-E Ortmann; C McNeill; R C Woodman; A Hochhaus; P D le Coutre; G Saglio
Journal:  Leukemia       Date:  2013-03-05       Impact factor: 11.528
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.